The antipsychotics. A pediatric perspective (Q40829185)

24 September 2017

1 reference

title

The antipsychotics. A pediatric perspective (English)

1 reference

24 September 2017

1

Findling RL

1 reference

24 September 2017

4

Blumer JL

1 reference

24 September 2017

Schulz SC

2

1 reference

PubMed ID

9884683

24 September 2017

Reed MD

series ordinal

3

1 reference

24 September 2017

1 October 1998

1 reference

Pediatric Clinics of North America

24 September 2017

1 reference

24 September 2017

45

1 reference

24 September 2017

5

1 reference

24 September 2017

1205-1232

1 reference

Subclinical hallucinations and delusions in nonpsychotic adolescents

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Response of psychotic depression subtypes to pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone in adolescents with schizophrenia: an open pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Rheumatic chorea controlled with haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Age at onset in subtypes of schizophrenic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Neuroleptic and antiepileptic treatment in the mentally retarded

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

The trial use of clozapine for abnormal involuntary movement disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine for treatment-refractory mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Drugs in aggressive behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Extrapyramidal reactions in adolescents treated with high-potency antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Seizure threshold in electroconvulsive therapy: I. Initial seizure threshold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clinical and therapeutic aspects of anorexia nervosa—a study of 30 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone, weight gain, and bulimia nervosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Treatment and outcome of anorexia nervosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine in the treatment of psychotic refractory depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Treatment of psychotic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

Childhood hallucinations

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone and tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Phenothiazine drugs: structure-activity relationships explained by a conformation that mimics dopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Use of risperidone in pervasive developmental disorders: a case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine treatment of borderline patients: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clinical experience with risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine treatment of bipolar disorder in a young adolescent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Dose and plasma levels of nortriptyline and chlorpromazine in delusionally depressed adolescents and of nortriptyline in nondelusionally depressed adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Fluphenazine and multifocal tic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Calcium channel blockade: possible explanation for thioridazine's peripheral side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Epidemiology of early-onset schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

Clozapine and seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Photosensitivity associated with antipsychotics, antidepressants and anxiolytics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Adverse effects of clomipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone and explosive aggressive autism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Psychiatric disorders in children and adolescents with mental retardation and developmental disabilities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Neuroleptic treatment of schizotypal personality disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Prescribing practices of outpatient child psychiatrists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Serotonin-dopamine interaction and its relevance to schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Galactorrhea: a study of 235 cases, including 48 with pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Acute laryngeal dystonic reactions to neuroleptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Hallucinatory experiences in nonpsychotic children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Neuroleptic malignant syndrome in children and adolescents: two case reports and a warning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Differentiating neuroleptic-related heatstroke from neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine for tardive dyskinesia in adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Sex difference in age at onset of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone in children with schizophrenia -letter-

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Ophthalmologic effects of psychotropic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Anorexia nervosa and the regulation of intake: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Major depression and conduct disorder in prepuberty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Suicide among female adolescents: characteristics and comparison with males in the age group 13 to 22 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone-induced neuroleptic malignant syndrome in young patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Dosage of haloperidol for mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Hallucinatory Phenomena in Childhood: A Critique of the Literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Seroquel: biochemical profile of a potential atypical antipsychotic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Pimozide treatment of Sydenham's chorea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Controlled Study of Pimozide vs. Placebo in Tourette's Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Treatment of Sydenham's Chorea with Haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Dopamine receptors, neuroleptics, and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Efficacy of phenelzine and haloperidol in borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

The pharmacological treatment of delusional depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Neuroleptic drugs: indications and guidelines for their rational use in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Comparison of intramuscular meperidine and promethazine with and without chlorpromazine: a randomized, prospective, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Response to antipsychotic medication: the doctor's and the consumer's view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Risperidone-induced neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Methylphenidate and haloperidol in children. Effects on attention, memory, and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

The pathophysiology of extrapyramidal side-effects of neuroleptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Is there any drug treatment of choice for the borderline patient?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970070-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0031-3955(05)70070-5

1 reference

24 September 2017

1 reference

PubMed ID

9884683